N-PORT filing recap · January 2024

What did ARK Genomic Revolution ETF buy in January 2024?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.65B

Positions

Estimated turnover

18.5%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

LABStandard Biotools Inc.$30.45Mreported value+13.42M shares AMGNAmgen Inc.$8.95Mreported value+28.5K shares ABSIAbsci Corp$1.71Mreported value+430.9K shares

Increased positions

CRSPCrispr Therapeutics AG$109.29Mreported value+122.5K shares+7.6%RXRXRecursion Pharmaceuticals, Inc.$81.06Mreported value+1.13M shares+15.1%TXG10x Genomics, Inc.$54.03Mreported value+484.7K shares+59.7%MRNAModerna, Inc.$35.17Mreported value+57.3K shares

Reduced positions

EXASExact Sciences Corporation$135.37Mreported value-430.0K shares-17.2%TWSTTwist Bioscience Corporation$86.26Mreported value-192.4K shares-6.7%IONSIonis Pharmaceuticals, Inc.$75.61Mreported value-580.5K shares-28.3%TDOCTeladoc Health, Inc.$73.32Mreported value-153.7K shares

Exited positions

SLGCUSDSomalogic Inc$28.90Mprior reported value-12.96M shares-100.0%